Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta (γδ) T cells in a range of cancer indications and a portfolio of novel immunotherapies for the treatment of cancer and autoimmune diseases, announced today the closing of a $53 million (€48 million) Series B financing round. The round was co-led by Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), and Bpifrance through its InnoBio 2* and Large Venture funds and joined by new investors Wellington Partners, Agent Capital and Alexandria Venture Investments. [...]